Ellicott City, Maryland 21201

  • Glioma


The purpose of this study is to examine the safety and feasibility of performing hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess the accuracy of hyperpolarized metabolic MRI to diagnose intermediate to patients with infiltrating gliomas and examine the added utility of metabolic MRI over standard MRI imaging The FDA is allowing the use of hyperpolarized [1-13C] pyruvate (HP 13C-pyruvate) in this study. Up to 5 patients may take part in this study at the University of Maryland, Baltimore (UMB).


Inclusion Criteria: - • Patients with a new brain lesion interpreted as suspected infiltrating gliomas including but not limited to (diffuse astrocytoma WHO grade 2; oligodendroglioma WHO grade 2 and 3; anaplastic astrocytoma WHO grade 3; astrocytoma WHO grade 4), OR, patients with prior history of infiltrating glioma scheduled for surgery for tumor biopsy or resection. - Ages 18-80, including male and female - Suitable to undergo contrast-enhanced MRI - Negative serum pregnancy test Exclusion Criteria: - Inability to undergo MRI scan - Inability to receive IV contrast secondary to severe reaction or renal insufficiency.



Primary Contact:

Ranyah Almardawi
Phone: 4103285562
Email: ranyahalmardawi@umm.edu

Backup Contact:


Location Contact:

Ellicott City, Maryland 21201
United States

Ranyah Almardawi
Phone: 410-328-5562
Email: ranyahalmardawi@umm.edu

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: June 21, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.